
Maximilian Larena

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6606485/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Unveiling the Genetic History of the Maniq, a Primary Hunter-Gatherer Society. Genome Biology and Evolution, 2022, 14, .	2.5	5
2	Episodes of Diversification and Isolation in Island Southeast Asian and Near Oceanian Male Lineages. Molecular Biology and Evolution, 2022, 39, .	8.9	9
3	Multiple migrations to the Philippines during the last 50,000 years. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	50
4	Genomic insights into population history and biological adaptation in Oceania. Nature, 2021, 592, 583-589.	27.8	100
5	Philippine Ayta possess the highest level of Denisovan ancestry in the world. Current Biology, 2021, 31, 4219-4230.e10.	3.9	37
6	Requirement for Cyclic AMP/Protein Kinase A-Dependent Canonical NFκB Signaling in the Adjuvant Action of Cholera Toxin and Its Non-toxic Derivative mmCT. Frontiers in Immunology, 2019, 10, 269.	4.8	10
7	Proteomic analysis of cholera toxin adjuvant-stimulated human monocytes identifies Thrombospondin-1 and Integrin-β1 as strongly upregulated molecules involved in adjuvant activity. Scientific Reports, 2019, 9, 2812.	3.3	9
8	Partial dysfunction of STAT1 profoundly reduces host resistance to flaviviral infection. Virology, 2017, 506, 1-6.	2.4	4
9	Deficiency in Calcium-Binding Protein S100A4 Impairs the Adjuvant Action of Cholera Toxin. Frontiers in Immunology, 2017, 8, 1119.	4.8	13
10	Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae. Vaccine, 2016, 34, 2121-2128.	3.8	34
11	Cholera Toxin, and the Related Nontoxic Adjuvants mmCT and dmLT, Promote Human Th17 Responses via Cyclic AMP–Protein Kinase A and Inflammasome-Dependent IL-1 Signaling. Journal of Immunology, 2015, 194, 3829-3839.	0.8	63
12	Internal Ribosome Entry Site-Based Attenuation of a Flavivirus Candidate Vaccine and Evaluation of the Effect of Beta Interferon Coexpression on Vaccine Properties. Journal of Virology, 2014, 88, 2056-2070.	3.4	6
13	JE-ADVAX Vaccine Protection against Japanese Encephalitis Virus Mediated by Memory B Cells in the Absence of CD8 ⁺ T Cells and Pre-Exposure Neutralizing Antibody. Journal of Virology, 2013, 87, 4395-4402.	3.4	46
14	Cytolytic effector pathways and <scp>IFN</scp> â€i³ help protect against <scp>J</scp> apanese encephalitis. European Journal of Immunology, 2013, 43, 1789-1798.	2.9	48
15	An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing Antibody. Journal of Virology, 2013, 87, 10324-10333.	3.4	73
16	The Chemokine Receptor CCR5, a Therapeutic Target for HIV/AIDS Antagonists, Is Critical for Recovery in a Mouse Model of Japanese Encephalitis. PLoS ONE, 2012, 7, e44834.	2.5	34
17	Immunobiology of Japanese Encephalitis Virus. , 2011, , .		5
18	Pivotal Role of Antibody and Subsidiary Contribution of CD8 ⁺ T Cells to Recovery from Infection in a Murine Model of Japanese Encephalitis. Journal of Virology, 2011, 85, 5446-5455.	3.4	74

#	Article	IF	CITATIONS
19	Live Chimeric and Inactivated Japanese Encephalitis Virus Vaccines Differ in Their Cross-Protective Values against Murray Valley Encephalitis Virus. Journal of Virology, 2009, 83, 2436-2445.	3.4	53